PulseAGGREGATOR

Home Feed Stories Sources Features

PulseAGGREGATOR

Gathering headlines…

Pulse Aggregator

Your news command center for 10,000+ sources. Search, filter, and set alerts — then cut through the noise with bias analysis, story clustering, and blindspot detection.

Endpoints News

healthCenter

6h ago

Superluminal secures $60M for Phase 1 of genetic obesity drugtranslating…

A Boston biotech following in the footsteps of Rhythm Pharmaceuticals and others in the MC4R obesity field has raised $60 million to test its approach in Phase 1.

 Superluminal Medicines secured the Series B from ...

Factuality

76/100

Political Bias

Center

Ownership

Endpoints News

Country

USA

Region

North America

Language

English

Keywords#Phase#Superluminal#obesity#health

Read Original ↗ Article view

Comments

Loading comments…

Superluminal secures $60M for Phase 1 of genetic obesity drug | Pulse Aggregator